Decision Benefits North Carolina Medicaid Patients with Chronic Wounds

NEWPORT NEWS, Virginia (August 28, 2013) – Effective immediately, the North Carolina Division of Medical Assistance (Medicaid and Health Choice), will provide coverage for the use of TheraSkin®, a real skin therapy that effectively treats chronic wounds, on diabetic foot ulcers and venous leg ulcers. This decision dovetails with the NC Dept. of Health and Human Services that “All North Carolinians will enjoy optimal health and well-being.”

“We applaud the decision by the NC Medicaid Program to cover this limb and life-saving product, ” said Kerry McCarter, CEO of Soluble Systems, LLC, the parent company of TheraSkin, explaining that North Carolina residents with diabetic and venous leg ulcers will now have access to cost-effective living cell therapy.

Patients who have particularly benefited from the wound healing capabilities of TheraSkin are those with diabetes. The percentage of NC residents that suffer from diabetes has increased 33% over the last ten years, to about 10% or 800,000 people.

“Diabetics are likely to develop foot ulcers, which are often extremely difficult to heal,” explained McCarter. “When all else fails, these patients are involved in nearly two-thirds of all non-traumatic lower limb amputations each year.” TheraSkin clinical results demonstrate the potential to save many patients from these life-threatening lower limb amputations by effectively closing over 60% of previously “non-healing” diabetic andvenous ulcers in 12 weeks.

“We will work tirelessly with the medical institutions and practitioners in North Carolina to help implement the clinical and economic benefits of TheraSkin,” said Allan Staley, President of Soluble Systems.

TheraSkin is not only clinically effective, but economical, costing 50 – 70% less than competing biologically active products, saving patients and the NC Medicaid program thousands of dollars per treatment. A potent new weapon in the battle against rising healthcare costs, TheraSkin has the potential to save patients and the U.S. healthcare system more than $1 billion over the next decade.

TheraSkin is a biologically active cryo-preserved human skin allograft for non-responsive chronic wounds. Its fully developed extracellular matrix (ECM) and living cells provide an “at-ready” supply of human growth factors, cytokines and collagen to jumpstart wound healing. Like competing biologically active skin substitutes, TheraSkin provides necessary growth factors and cytokines to treat chronic wounds; however, it also provides a large quantity of essential human collagens in appropriate ratios to support healing.